CA3070790C - Anticorps anti-ctla-4 et leurs utilisations - Google Patents

Anticorps anti-ctla-4 et leurs utilisations

Info

Publication number
CA3070790C
CA3070790C CA3070790A CA3070790A CA3070790C CA 3070790 C CA3070790 C CA 3070790C CA 3070790 A CA3070790 A CA 3070790A CA 3070790 A CA3070790 A CA 3070790A CA 3070790 C CA3070790 C CA 3070790C
Authority
CA
Canada
Prior art keywords
antibody
antigen
ctla
binding fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3070790A
Other languages
English (en)
Other versions
CA3070790A1 (fr
Inventor
Aynur HERMANN
Ella Ioffe
Elena Burova
Gavin Thurston
William Olson
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority claimed from PCT/US2018/043936 external-priority patent/WO2019023482A1/fr
Publication of CA3070790A1 publication Critical patent/CA3070790A1/fr
Application granted granted Critical
Publication of CA3070790C publication Critical patent/CA3070790C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des anticorps qui se lient à la protéine associée au lymphocyte T cytotoxique (CTLA-4), et leurs procédés d'utilisation. Dans divers modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à CTLA-4. Dans certains modes de réalisation, les anticorps de l'invention sont utiles pour inhiber ou neutraliser l'activité de CTLA-4, produisant ainsi un moyen d'activer les lymphocytes T et/ou de traiter une maladie ou un trouble tel qu'un cancer ou une infection virale.
CA3070790A 2017-07-27 2018-07-26 Anticorps anti-ctla-4 et leurs utilisations Active CA3070790C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762537753P 2017-07-27 2017-07-27
US62/537,753 2017-07-27
US201762588853P 2017-11-20 2017-11-20
US62/588,853 2017-11-20
US201862645284P 2018-03-20 2018-03-20
US62/645,284 2018-03-20
US201862685599P 2018-06-15 2018-06-15
US62/685,599 2018-06-15
PCT/US2018/043936 WO2019023482A1 (fr) 2017-07-27 2018-07-26 Anticorps anti-ctla-4 et leurs utilisations

Publications (2)

Publication Number Publication Date
CA3070790A1 CA3070790A1 (fr) 2019-01-31
CA3070790C true CA3070790C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
US20250122307A1 (en) Anti-CTLA-4 Antibodies and Uses Thereof
JP7562606B2 (ja) Ｐｄ－１に対するヒト抗体
US20240166740A1 (en) Anti-lag3 antibodies and uses thereof
BR112016016207B1 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção e seus usos, composição farmacêutica e seus usos, molécula de polinucleotídeo isolada, e vetor isolado
CA3070790C (fr) Anticorps anti-ctla-4 et leurs utilisations
CA3000209C (fr) Anticorps anti-lag3 et leurs utilisations
EA042000B1 (ru) Анти-ctla-4 антитела и их применение
EA039718B1 (ru) Антитела к lag3 и их применения
NZ721656B2 (en) Human antibodies to pd-l1
BR112016016699B1 (pt) Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a pd-1, método de produção e usos do mesmo, composição farmacêutica, molécula de polinucleotídeo isolada, e vetor